Tanios Bekaii-Saab, MD, discusses how community oncologists can play an important role in the advancement of gastrointestinal (GI) cancers despite not having access to major trials.
Tanios Bekaii-Saab, MD, a professor of medicine at the Mayo Clinic, discusses how community oncologists can play an important role in the advancement of gastrointestinal (GI) cancers despite not having access to major trials.
Now, more than ever, there is a better understanding of alterations, mutations, amplifications, and fusions that are drivers, Bekaii-Saab says. Many studies now are looking at colorectal cancer to develop agents for the various subgroups.
Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback
July 18th 2024Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More